Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?

Bruselle and Riemann discuss the study by Corren and colleagues on the efficacy of tezepelumab independent of severe asthma phenotype. Pooling data from these two placebo-controlled, double-blind, randomized trials increased statistical power, enabling precise estimates of the efficacy of tezepelumab across multiple clinically relevant phenotypes. All patients had at least two exacerbations during the year before enrollment. This post hoc pooled analysis of the PATHWAY and NAVIGATOR studies thus demonstrates the efficacy of tezepelumab in a broad population with severe asthma, including patients with type 2-low asthma. Tezepelumab is the first biologic to show a significant, albeit modest, AAER in type 2-low severe asthma. However, the magnitude of the therapeutic response to tezepelumab significantly increases with increasing BEC or FeNO, suggesting that its efficacy is at least partially dependent on asthma phenotype.